Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
26 juin 2024 07h00 HE
|
Lyell Immunopharma, Inc
Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date...
Fatty15 Nabs Prestigious 2024 Mindful Award For “Overall Supplement Product of the Year”
11 juin 2024 08h05 HE
|
Mindful Awards
LOS ANGELES, June 11, 2024 (GLOBE NEWSWIRE) -- The 2024 Mindful Awards Program, an independent recognition platform highlighting conscious companies and products that mindfully make waves in the...
Latest] India Electric Vehicle Market Size/Share Worth USD 150.2 Billion by 2032 at a 25.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
25 mars 2024 15h00 HE
|
Custom Market Insights
Austin, TX, USA, March 26, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “India Electric Vehicle Market Size, Trends and Insights By Propulsion Type...
Cell Line Development Market Exclusive Report 2024-2031 | InsightAce Analytic
23 janv. 2024 08h39 HE
|
InsightAce Analytic Pvt. LTd.
Jersey City, NJ, Jan. 23, 2024 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cell Line Development Market - (By Source of Cell...
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 16h05 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
09 nov. 2023 16h05 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Garuda Therapeutics Named “Overall Cell Biology Company of the Year” By BioTech Breakthrough
08 nov. 2023 08h03 HE
|
BioTech Breakthrough
LOS ANGELES, Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology...
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – DBTX, CELL, CCF, AGE
12 sept. 2023 14h01 HE
|
Monteverde & Associates PC
NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
Moore Kuehn Encourages CELL, CCF, IMNM, and KLR Investors to Contact Law Firm
11 sept. 2023 10h40 HE
|
Moore Kuehn
NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – HCCI, CEQP, CELL, CTG
05 sept. 2023 19h34 HE
|
Monteverde & Associates PC
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...